Aumento do Risco Cardiovascular em Pacientes com Câncer de Mama

Ana Flávia Ricardo de Macêdo Pessoa; Beatriz de Lima Moura; Luana Casagranda; Pedro Henrique Macêdo de Almeida; Rebecka Marques Gomes Sagratzki; Gabriel Girão de Araújo; Savigny Paulino Maximino Rodrigues; Aloiso Sampaio Souza

doi:10.36489/saudecoletiva.2026v18i111p20568-20589

Authors

Ana Flávia Ricardo de Macêdo Pessoa Graduanda em Medicina – Afya Faculdade de Ciências Médicas de Bragança https://orcid.org/0009-0009-3939-9243
Beatriz de Lima Moura Graduanda em Medicina – Afya Faculdade de Ciências Médicas de Bragança https://orcid.org/0000-0003-3469-4760
Luana Casagranda Graduanda em Medicina – Faculdade Nova Esperança (FAMENE) https://orcid.org/0009-0005-1668-1802
Pedro Henrique Macêdo de Almeida Médico – Centro Universitário Facisa (UNIFACISA) https://orcid.org/0009-0008-7329-0818
Rebecka Marques Gomes Sagratzki Graduanda em Medicina – Faculdade Nova Esperança (FAMENE) https://orcid.org/0009-0002-5912-1838
Gabriel Girão de Araújo Graduando de Medicina – Faculdade Nova Esperança (FAMENE). https://orcid.org/0009-0007-7577-4798
Savigny Paulino Maximino Rodrigues Graduando de Medicina – Faculdade Nova Esperança (FAMENE). https://orcid.org/0009-0008-5708-4029
Aloiso Sampaio Souza Médico – Universidade Federal do Maranhão (UFMA); Docente – Afya Faculdade de Ciências Médicas de Bragança https://orcid.org/0000-0002-5924-7994

DOI:

https://doi.org/10.36489/saudecoletiva.2026v18i111p20568-20589

Keywords:

Neoplasias da Mama, Fatores de Risco Cardiovascular, Cardio-Oncologia, Cardiotoxicidade, Saúde da Mulher

Abstract

Breast cancer is associated with increased cardiovascular risk, as cardiovascular diseases are the leading cause of non-oncological death in this population. This Integrative Review analyzed 46 articles selected from PubMed/MEDLINE, SciELO, and Europe PMC databases, aiming to synthesize evidence on the pathophysiological mechanisms, cardiotoxic agents, and cardiovascular prevention and monitoring strategies in breast cancer patients. The findings showed that anthracyclines, trastuzumab, aromatase inhibitors, CDK 4/6 inhibitors, and thoracic radiotherapy are the main therapies inducing cardiotoxicity, and are potentiated by risk factors such as obesity, hypertension, metabolic syndrome, and induced menopause. Cardiac biomarkers and global longitudinal strain demonstrated superiority in the early detection of subclinical cardiac dysfunction. Therefore, the integration between cardiology and oncology, with individualized risk stratification and longitudinal follow-up, are essential for reducing cardiovascular morbidity and mortality among breast cancer patients and survivors.

References

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of Anticancer Treatments: Epidemiology,Detection, and Management. CA: A Cancer Journal for CliniciansCardiotoxicity of Anticancer Treatments. 2016;66:309-325.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-801.

Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30-66.

Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537-55.

Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6-13.

Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34(10):1122-30.

Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017;47(8):1-5.

Lee Chuy K, Yu AF. Cardiotoxicity of contemporary breast cancer treatments. Curr Treat Options Oncol. 2019;20:51.

Marek J, Linhart A, Rucklová Z, Haber J, Korínek J. Cardiotoxicity of cancer therapy. Vnitrni Lekarstvi. 2011;57(5):472-484.

Loap P, Kirov K, Kirova Y. Cardiotoxicity in breast cancer patients treated with radiation therapy: from clinical imaging to dosimetry. Critical Reviews in Oncology/Hematology. 2020;156:103121.

Buttros DAB, Nahas EAP, Branco MT, Orsatti CL, Almeida-Filho BS, Nahas-Neto J, Nahas EAP. High risk for cardiovascular disease in postmenopausal breast cancer survivors. Menopause: The Journal of The North American Menopause Society. 2019;26(5):1024-1030.

Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32(7):831-41.

Yeh TL, Hsu MS, Hsu HY, Tsai MC, Jhuang JR, Chiang CJ, et al. Risk of cardiovascular diseases in cancer patients: a nationwide representative cohort study in Taiwan. BMC Cancer. 2022;22:1198.

Ng HS, Meng R, Marin TS, Damarell RC, Buckley E, Selvanayagam JB, et al. Cardiovascular mortality in people with cancer compared to the general population: a systematic review and meta-analysis. Cancer Med. 2024;13(15):e70057.

Guan T, Li Y, Zhang H, Yang J, Liu W, Wang K, Su M, et al. Increased risk of cardiovascular death in breast cancer patients without chemotherapy or (and) radiotherapy: a large population-based study. Front Oncol. 2021;10:619622.

Felicetti F, Fortunati N, Brignardello E. Cancer survivors: an expanding population with an increased cardiometabolic risk. Diabetes Res Clin Pract. 2018;143:432-42.

Van Westerop LLM, Arts-de Jong M, de Hullu JA, IntHout J, Hoogerbrugge N, Maas AHEM. Cardiovascular risk of BRCA1/2 mutation carriers: a review. Maturitas. 2016;91:135-9.

Mazzuti FS, Custódio IDD, Lima MTM, Carvalho KP, Pereira TSS, Molina MCB, et al. Breast cancer survivors undergoing endocrine therapy have a worrying risk factor profile for cardiovascular diseases. Nutrients. 2021;13(4):1114.

Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34(26):3157-65.

Melson JW, Bhagat AA, Jenkins SM, Bjornsson T, Herrmann J, Villarraga HR, et al. Atherosclerotic cardiovascular disease risk and longitudinal risk factor management among patients with breast cancer. Clin Breast Cancer. 2023;24(2):e71-e79.

Jones DH, Nestore M, Henophy S, Cousin J, Comtois AS. Increased cardiovascular risk factors in breast cancer survivors identified by routine measurements of body composition, resting heart rate and arterial blood pressure. Springerplus. 2014;3:150.

Hershman DL, Accordino MK, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Hur C, et al. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 2020;126(7):1541-49.

Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Cardiovascular risk in postmenopausal women with and without breast cancer. Eur J Obstet Gynecol Reprod Biol. 2014;183:10-11.

Zhang M, Yang H, Xu C, Jin F, Zheng A. Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment: a meta-analysis. Front Oncol. 2022;12:899782.

Jin H, Xu J, Sui Z, Wang L. Risk factors from Framingham risk score for anthracycline cardiotoxicity in breast cancer: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1101585.

Rozner RN, Frishman WH. Cardiovascular effects of chemotherapy used in the treatment of breast cancers. Cardiol in Rev. 2019;27:87-96.

Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-45.

Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore). 2016;95(44):e5195.

Taha AM, Odat RM, Moawad WAE, Saed SAA, Amer BE, Nguyen D, Tran L, et al. Safety of permissive cardiotoxicity of trastuzumab in patients with breast cancer: a systematic review and meta-analysis. Cardiovasc Toxicol. 2025;25(9):1369-80.

Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L, Gori S. Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer. 2016;17(1):11-7.

Yoo JJ, Jung E, Kim Z, Kim B. Risk of cardiovascular events and lipid profile change in patients with breast cancer taking aromatase inhibitor: a systematic review and meta-analysis. Curr Oncol. 2023;30(2):1831-43.

Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, Smeeth L, Bhaskaran K. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.

Matthews AA, Hinton SP, Stanway S, Lyon AR, Smeeth L, Lund JL, Bhaskaran K. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2020; 0:1-9.

Liu YS, Dong K, Park C. Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: a systematic review and network meta-analysis. Rev Cardiovasc Med. 2023;24(11):309.

Díaz-Gavela AA, Figueiras-Graillet L, Luis AM, Segura JS, Ciérvide R, Peñalver EC, Couñago F, Arenas M, et al. Breast radiotherapy-related cardiotoxicity. When, how, why. Risk prevention and control strategies. Cancers. 2021;13:1712.

Zhu Q, Kirova YM, Cao L, Arsene-Henry A, Chen J. Cardiotoxicity associated with radiotherapy in breast cancer: a question-based review with current literatures. Cancer Treat Rev. 2018;68:9-15.

Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, Aakhus S, Miyazaki S, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2020;77(4):392-401.

Wang Z, Wu Y, He J, Liu Y, Li Y, Zhao X, et al. Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. ESC Heart Fail. 2025;12(6):4194-4207.

Masum K, Sriniva S, Ramaiah B. Rare manifestation of paclitaxel-induced cardiotoxicity: a case of restrictive cardiomyopathy in an elderly breast cancer patient. Indian Journal of Pharmacology. 2026;58(2):150-152.

Banke A, Fosbol EL, Moller JE, Gislason GH, Andersen M, Bernsdorf M, Jensen M, Schou M, et al. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail. 2018;20(10):1447-1453.

Bhuiyan MZR, Hoque H, Alam S. Effective management of chemotherapy-induced cardiotoxicity: a prospective follow-up study on alternative regimens in Bangladeshi cancer patients. Cureus. 2026;18(3):e104843.

Ling JY, Wen LM, Liu K, Yuan W, Zhong Y, Lai P, Liao Y. Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends. Discover Oncology. 2026;17(392):1-15.

Nelson-Veniard M, Thambo JB. Chemotherapy-induced cardiotoxicity: incidence, diagnosis and prevention. Bulletin du Cancer. 2015; 102(7-8):622-626.

Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005;5(4):233-43.

Monsuez JJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis. 2012;105(11):593-604.

Toledo-Chávarri A, Duarte-Díaz A, Álvarez-Pérez Y, Padilla-Ruiz M, Jansana A, Sala M. Long-term breast cancer survivors: experiences, needs, and proposals for person-centred care. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2026;34(5):466.